Stay updated on Satralizumab in Generalized Myasthenia Gravis Clinical Trial
Sign up to get notified when there's something new on the Satralizumab in Generalized Myasthenia Gravis Clinical Trial page.

Latest updates to the Satralizumab in Generalized Myasthenia Gravis Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe study has been terminated, and the sponsor has decided to halt development of satralizumab in generalized myasthenia gravis. Additionally, the number of study locations has decreased from 86 to 76, and several specific locations have been updated or removed.SummaryDifference100%
- Check35 days agoNo Change Detected
- Check42 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check49 days agoChange DetectedThe website has updated to version v2.14.2, adding 'Results Submitted' while removing 'No Results Posted' from the previous version v2.14.1.SummaryDifference0.2%
- Check64 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check71 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant revision.SummaryDifference0.2%
- Check100 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
Stay in the know with updates to Satralizumab in Generalized Myasthenia Gravis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Satralizumab in Generalized Myasthenia Gravis Clinical Trial page.